Skip to main content
AmigoFish

BackTable Urology

BackTable Inc.Audio

Format:
Podcast
New episodes:
Several times a week
Typical length:
about 50 minutes
Latest episode:
Not rated yet

About this show

The BackTable Urology Podcast is a resource for practicing urologists to learn tips, techniques, and practical advice from their peers in the field. Listen here or on the streaming platform of your choice.

Show details and episodes come from the publisher's public feed at feeds.megaphone.fm. Last updated . Names, artwork and text belong to their publishers.

Cosmos

Similar by topic and creator

See the full Cosmos

Similar shows

See all Education shows

Explore more

Episodes

  • Ep. 344 Insights into RVUs: Historical Context & Recent Changes with Dr. Kyle Richards

    · 50 min

    If you’ve felt penalized for getting faster in the OR, you’re not imagining it. On this episode of BackTable Urology, Dr. Ruchika Talwar interviews Dr. Kyle Richards, urologic oncologist at the University of Wisconsin and the American Urological Association's (AUA) representative on the RVS Update Committee (RUC), about how relative value units (RVUs) are set and who decides what a procedure is worth. Dr. Richards traces RVUs from their 1989 origins to the physician surveys behind every recommendation the RUC sends to Medicare, explains how a new technology earns a CPT code and a value, and shares why urology's single seat on the 31-member committee makes every survey response count. --- Get the BackTable app https://www.backtable.com/app --- This podcast was developed in collaboration with Society of Urologic Oncology https://suonet.org/home --- Timestamps 00:00 - Introduction 02:27 - What Is an RVU? 05:31 - Who Decides What a Procedure Is Worth 08:04 - How the RUC Works With CMS 10:10 - New Technology and New CPT Codes 13:32 - Inside the RUC Survey 18:26 - Who Sits on the RUC and How It Votes 22:08 - Budget Neutrality and the Conversion Factor 25:04 - Is Efficiency Being Penalized? 29:27 - New Codes for Retroperitoneal Cytoreduction 33:09 - Prostate Biopsy Codes and Practice Expense 36:47 - How Robotic Prostatectomy Has Been Valued 45:46 - How Urologists Can Get Involved --- More about this episode Dr. Kyle Richards explains how shorter intra-service times, budget neutrality, and Medicare's recent efficiency adjustment push RVUs down as procedures get faster, why practice expense makes up nearly half of a procedure's total RVUs, and why publications that showcase the fastest surgeon can make an appeal harder. He highlights recent wins for urology, including new codes for retroperitoneal cytoreduction after chemotherapy and for fusion, MRI-guided, and transperineal prostate biopsy, and tells the full story of how robotic prostatectomy has been valued, cut, appealed, and bundled with lymph node dissection. His advice for urologists who want a voice is simple: fill out the RUC survey when it arrives, report honest operative times, and get involved through the AUA and state medical societies. --- Resources American Medical Association: RVS Update Committee (RUC) https://www.ama-assn.org/about/rvs-update-committee-ruc Fix Medicare Now (American Medical Association) https://fixmedicarenow.org Leow JJ, et al. Robot-assisted Versus Open Radical Prostatectomy: A Contemporary Analysis of an All-payer Discharge Database. Eur Urol. 2016 https://doi.org/10.1016/j.eururo.2016.01.044 Hsiao WC, et al. Estimating physicians' work for a resource-based relative-value scale. N Engl J Med. 1988 https://doi.org/10.1056/NEJM198809293191305 --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

    Not rated yet
  • Ep. 343 Direct Contracting in Healthcare with Mark Cuban

    · 55 min

    “No cancer patient ever got healthier because their claim was denied and delayed. None. Not one.” Mark Cuban's verdict will ring true for any urologist who has fought a denied or delayed claim, and his alternative is a contract that starts by trusting the doctor. On this episode of BackTable Urology, Dr. Ruchika Talwar, urologic oncologist and value-based care leader, talks with Mark Cuban, entrepreneur and founder of Mark Cuban Cost Plus Drug Company, about who actually sets the price of care in the United States. They trace how a cold email about drug shortages led to Cost Plus Drugs and then Cost Plus Wellness, an open source library of direct contracts between self-insured employers and providers, and why he believes the contract, not the published price, is where the real problems hide. By his estimate, 67% of people with job-based coverage get it through a self-insured employer, which makes employers, not insurers, the real payers in American healthcare. --- Get the BackTable app https://www.backtable.com/app --- Timestamps 00:00 - Introduction 01:53 - From Drug Shortages to Cost Plus Drugs 06:08 - Cost Plus Wellness and Direct Contracts 11:04 - Publishing Provider Contracts 16:39 - Using AI to Review Contracts and RFPs 20:16 - Direct Contracting Advice for Hospitals and Physicians 26:33 - Value-Based Care, Brokers, and Self-Insured Hospitals 32:09 - Direct Contracting for Independent Practices 34:20 - AI as a Business Adviser for Physicians 38:39 - National Policy and Who Pays for Healthcare 46:59 - Misaligned Incentives and Corporate Culture 51:00 - Key Takeaways 54:04 - Closing Remarks --- More about this episode The conversation then turns practical for physicians. Mark Cuban lays out how hospitals, clinics, and independent practices can find the self-insured employers among their own patients and offer direct contracts or carve-outs, why a promise to trust the doctor can earn employers a better rate, and how he runs contracts that stretch past a thousand pages through several AI models in turn. He and Dr. Talwar also cover what employers can learn from Form 5500 filings, the national changes he would make, from ending gag clauses to standardized public contracts, and why both see misaligned incentives as the root of the problem. --- Resources Mark Cuban Cost Plus Drug Company https://costplusdrugs.com Cost Plus Wellness: an open source initiative by Mark Cuban https://costpluswellness.com Mark Cuban dives into direct contracting. Becker's Hospital Review. 2026 https://www.beckershospitalreview.com/finance/mark-cuban-dives-into-direct-hospital-contracting/ Form 5500 filings search (EFAST2), U.S. Department of Labor https://www.efast.dol.gov/welcome.html KFF. 2025 Employer Health Benefits Survey https://www.kff.org/health-costs/2025-employer-health-benefits-survey/ Gag Clause Prohibition Compliance Attestation. Centers for Medicare & Medicaid Services https://www.cms.gov/marketplace/about/oversight/other-insurance-protections/gag-clause-prohibition-compliance-attestation New generic drug company named after Mark Cuban first founded by a part-time radiologist. Health Imaging https://healthimaging.com/topics/healthcare-management/medical-practice-management/mark-cuban-generic-drug-company Dr. Ruchika Talwar, BackTable Urology contributor page https://www.backtable.com/shows/urology/contributors/dr-ruchika-talwar --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

    Not rated yet
  • Ep. 342 Mid-Career Urology: Understanding Career Evolution & Challenges with Dr. Debra Fromer and Dr. Anne Suskind

    · 35 min

    Mid-career is the stretch when you are no longer the new person on the block, but not yet the one in charge, and it gets far less attention than the years on either side of it. On this episode of BackTable Urology, presented in collaboration with the Society of Women in Urology (SWIU), Dr. Michelle Van Kuiken talks with Dr. Debra Fromer and Dr. Anne Suskind, both urology division chiefs and faculty vice chairs, about what no one tells you about mid-career. They describe how to know you have arrived there, why boredom can be the clearest signal that it is time to change, and why mid-career is the moment to say yes to a leadership role you have never trained for, even if what you learn is that you do not like it. --- Get the BackTable app https://www.backtable.com/app --- This podcast was developed in collaboration with Society of Women in Urology https://swiu.org/home.aspx --- Timestamps 00:00 - Introduction 01:50 - Defining Mid-Career 04:05 - Career as an Evolution 07:21 - Plateaus, Boredom, and Burnout 09:55 - Imposter Syndrome and New Leadership Roles 11:37 - Traps That Stall Mid-Career Growth 15:14 - Changing Expectations at Work and at Home 18:17 - Redefining Success 20:51 - Mentorship at Every Career Stage 22:26 - Phasing Out and Legacy 25:11 - Staying Motivated 27:38 - Life Outside Work 31:10 - Parting Words and Closing Remarks --- More about this episode The three surgeons then name the traps that stall growth, from support that falls away after the junior years to unrecognized, unpaid roles and the competing demands of young children and aging parents. Dr. Fromer explains why control over her own time has always been her measure of success, and Dr. Suskind makes the case for new mentors and peer mentors at every stage. They close on phasing out and legacy, what keeps them motivated, and how challenges outside the hospital, from leading a urology Battle of the Bands to tournament golf, can feed a career. --- Resources Society of Women in Urology (SWIU) https://www.swiu.org New York Section of the American Urological Association https://www.nyaua.com Docs Who Rock Raise More than $10,000 for Important Urological Initiatives. HMH Maestro, 2025 https://hmhmaestro.org/en/topics/featured-physicians/2025/04/21/docs-who-rock-raise-more-than-10000-for-important-urological-initiatives Dr. Michelle Van Kuiken, BackTable Urology contributor page https://www.backtable.com/shows/urology/contributors/dr-michelle-van-kuiken --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

    Not rated yet
  • Ep. 341 Understanding Overactive Bladder in Male Patients with Dr. Bilal Chughtai

    · 40 min

    How many prostate medications and procedures should a man try before anyone checks his bladder? Dr. Bilal Chughtai has met men who worked through an alpha blocker, add-on medications, a minimally invasive prostate procedure, and even resective surgery before anyone named overactive bladder as part of the problem. On this episode of BackTable Urology, Dr. Anjali Kapur, urogynecologist at Hackensack Meridian Health, welcomes Dr. Chughtai, chief of urology at Northwell Health's Plainview and Syosset hospitals, to rethink how urologists separate overactive bladder (OAB) from benign prostatic hyperplasia (BPH) in men. Dr. Chughtai explains how he reads the storage and voiding items of the International Prostate Symptom Score (IPSS), why he usually starts with a beta-3 agonist rather than an anticholinergic, how he trims polypharmacy one medication holiday at a time, and when urodynamics helps decide whether to treat the prostate, the bladder, or both. --- Get the BackTable app https://www.backtable.com/app --- This podcast is supported by Sumitomo Pharma America, Inc. https://www.us.sumitomo-pharma.com/ --- Timestamps 00:00 - Introduction 02:37 - Initial Evaluation and First-Line Therapy 06:11 - Combination Therapy and Medication Holidays 09:37 - Reassessing Symptoms After an Outlet Procedure 11:59 - Botox and Neuromodulation in Men 15:14 - Persistent Symptoms After Prior BPH Treatment 18:44 - The COURAGE Trial and Urge Incontinence 23:22 - Combining Therapies and Setting Goals 25:48 - Questionnaires, Bladder Diaries, and Underreporting 29:05 - OAB Awareness in Primary Care 31:14 - Nocturia and Sleep Apnea 33:23 - Timing of Intervention and Bladder Health 38:04 - Final Takeaways and Closing Remarks --- More about this episode The two then turn to third-line therapy in men, including intradetrusor botulinum toxin, sacral neuromodulation, and tibial nerve stimulation, and to men whose storage symptoms persist or appear after an outlet procedure. Dr. Chughtai shares what the COURAGE trial of a beta-3 agonist added to BPH therapy taught him about asking men directly about urge incontinence, along with his goal of a 50% improvement in symptoms, the limits of questionnaires and bladder diaries, his research on OAB awareness in primary care, and the link between nocturia and sleep apnea. They close on the open question of when to treat the bladder before it changes, and why counseling should inform men without threatening them. --- Resources Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial. J Urol. 2024 https://pubmed.ncbi.nlm.nih.gov/38708869/ Vibegron for overactive bladder in men with benign prostatic hyperplasia/obstruction: insights from the COURAGE trial. Transl Androl Urol. 2025 https://pubmed.ncbi.nlm.nih.gov/40376518/ Lower Urinary Tract Symptoms Following Transurethral Resection of Prostate. Curr Urol Rep. 2018 https://pubmed.ncbi.nlm.nih.gov/30128964/ 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol. 1998 https://pubmed.ncbi.nlm.nih.gov/9628595/ The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder https://www.auanet.org/guidelines-and-quality/guidelines/idiopathic-overactive-bladder BackTable Urology Episode 138: Hood-Sparing & Greenlight Laser Therapy in BPH Management https://www.backtable.com/shows/urology/podcasts/138/hood-sparing-greenlight-laser-therapy-in-bph-management Dr. Bilal Chughtai, BackTable Urology contributor page https://www.backtable.com/shows/urology/contributors/dr-bilal-chughtai Dr. Anjali Kapur, BackTable Urology contributor page https://www.backtable.com/shows/urology/contributors/dr-anjali-kapur --- BackTable Urology is the go-to podcast for urologists,…

    Not rated yet
  • Ep. 340 Understanding Intermediate-Risk Bladder Cancer with Dr. Wesley Yip

    · 43 min

    By one estimate, half or more of all non-muscle invasive bladder cancer (NMIBC) is intermediate risk, yet the major guidelines still do not define it the same way, which leaves urologists sorting a large, mixed group of patients without a shared playbook for when to resect again, treat in the office, or start intravesical therapy. On this episode of BackTable Urology, Dr. Ruchika Talwar welcomes Dr. Wesley Yip, urologic oncologist at City of Hope, to rethink what she calls the forgotten stepchild of bladder cancer: intermediate-risk non-muscle invasive bladder cancer (NMIBC). Dr. Yip explains why he sees the category as a catch-all rather than a single biological entity, by his estimate covering 50 to 60 percent of NMIBC, why he now relies on the International Bladder Cancer Group (IBCG) definition, and why tumor grade comes first, ahead of multiplicity, size, and recurrence timing. --- Get the BackTable app https://www.backtable.com/app --- Timestamps 00:00 - Introduction 02:24 - Defining Intermediate-Risk NMIBC 07:53 - Case Presentation and the Initial TURBT 10:42 - Evaluating the First Recurrence 13:09 - High-Grade Cytology and Blue Light Cystoscopy 15:01 - The Burden of Repeat TURBT 16:57 - Office Fulguration and Chemoablation 20:23 - Chemoablation Tolerability and Patient Selection 24:24 - Intravesical Chemotherapy and Treatment Barriers 28:08 - New Formulations and Upcoming Trials 33:12 - Recurrence After Chemoablation and De-escalation 38:00 - Future Directions and Patient-Centered Endpoints 42:39 - Closing Remarks --- More about this episode Working through the case of a healthy 67-year-old man with recurrent low-grade Ta disease, the two discuss what to document at the first resection, how to counsel patients, when to return to the operating room, and when office fulguration, intravesical chemoablation, or intravesical chemotherapy with gemcitabine and docetaxel makes more sense. They cover the cumulative burden of repeat transurethral resection, practical lessons from bringing chemoablation into the clinic, how to read new trial data, and when to de-escalate surveillance. Dr. Yip closes with his hopes for the next five years: a biology-based definition and trials that measure fewer recurrences, fewer procedures, and better quality of life. --- Resources Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol. 2022 https://pubmed.ncbi.nlm.nih.gov/35718695/ Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group. Eur Urol Oncol. 2025 https://pubmed.ncbi.nlm.nih.gov/41076366/ All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors. J Urol. 2022 https://pubmed.ncbi.nlm.nih.gov/35770498/ Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline EAU Guidelines on Non-muscle-invasive Bladder Cancer https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer Bladder Cancer Advocacy Network (BCAN) https://bcan.org Dr. Wesley Yip, City of Hope physician profile https://www.cancercenter.com/physician-directory/wesley-yip Dr. Ruchika Talwar, BackTable Urology contributor page https://www.backtable.com/shows/urology/contributors/dr-ruchika-talwar --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

    Not rated yet
  • Ep. 339 AI's Role in Enhancing Urology Care with Dr. David Canes

    · 58 min

    By his own estimate, an AI scribe gives one urologist about two hours of his day back, and an evidence tool built into it has taught him something new in the clinic almost every day. On this episode of BackTable Urology, Dr. Ruchika Talwar welcomes back Dr. David Canes, urologist at Lahey Hospital & Medical Center and founder of WellPrept, to talk about how urologists can practically put AI to work. Dr. Canes explains why he sees this moment as a renaissance for physicians, how an AI scribe turned him from author into proofreader, by his estimate saving about two hours a day, and why evidence tools running alongside the scribe now answer questions in the exam room, including a question about post-prostatectomy dysorgasmia, a complaint that rarely comes up in clinic. --- Get the BackTable app https://www.backtable.com/app --- Timestamps 00:00 - Introduction 03:32 - Getting Started With AI in Practice 07:24 - AI Scribes and Cognitive Load 14:18 - AI Evidence Tools at the Point of Care 18:41 - Context, Pre-Charting, and Evidence in the Exam Room 24:52 - AI for Email and Personal Workflow 29:09 - Building a Permanent AI Memory 34:20 - AI Skepticism, Privacy, and Intellectual Honesty 40:47 - Will AI Replace Physicians? 46:39 - Pre-Charting, Patient Education, and Care Journeys 49:27 - Reducing the In-Basket Burden 53:04 - Where to Start With AI 55:27 - Closing Remarks --- More about this episode The conversation then moves beyond the clinic. Dr. Canes describes an AI layer on email that flags what cannot wait, and a permanent AI memory built from plain text files that keeps research, licenses, talks, and family life organized, with a firm rule that no protected health information goes anywhere without a business associate agreement. He and Dr. Talwar discuss what work is worth delegating to AI, push back on a recent JAMA perspective arguing that autonomous AI may outperform physicians, and run through tools for pre-charting, patient education, postoperative care journeys, and front-desk calls. Dr. Canes closes with simple advice for exhausted physicians: ask the AI you already use to build you a 90-day plan. --- Resources Will Autonomous AI Exceed AI-Aided Physicians as the Best Medical Care? JAMA. 2026 https://jamanetwork.com/journals/jama/fullarticle/2852952 The utility of tamsulosin in the management of orgasm-associated pain: a pilot analysis. Eur Urol. 2005 https://pubmed.ncbi.nlm.nih.gov/15716202/ WellPrept https://www.wellprept.com BackTable Urology Episode 55: Patient Preparation Made Easy: The WellPrept Story https://www.backtable.com/shows/urology/podcasts/55/patient-preparation-made-easy-the-wellprept-story Dr. David Canes, BackTable Urology contributor page https://www.backtable.com/shows/urology/contributors/dr-david-canes Dr. Ruchika Talwar, BackTable Urology contributor page https://www.backtable.com/shows/urology/contributors/dr-ruchika-talwar --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

    Not rated yet
  • Ep. 338 From Numbers to Decisions: Clinical Utility of Biomarkers in Prostate Cancer Diagnosis with Dr. Amir Lebastchi

    · 48 min

    Every prostate cancer biomarker returns a number, but the real question is whether that number changes what you do next for the patient. On this episode of BackTable Urology, Dr. Ruchika Talwar welcomes Dr. Amir Lebastchi, urologic oncologist at Keck Medicine of USC, to discuss how biomarkers are moving prostate cancer care from numbers to meaningful clinical decisions. They define what makes a biomarker clinically useful, organize the growing list of blood, urine, and tissue tests into pre-biopsy, post-negative-biopsy, and post-diagnosis settings, and talk through where these tests fit alongside MRI after an elevated PSA. --- Get the BackTable app https://www.backtable.com/app --- This podcast is supported by Cleveland Diagnostics https://www.isopsa.com/ --- Timestamps 00:00 - Introduction 02:59 - Clinical Utility and a Framework for Biomarkers 08:43 - Workup of an Elevated PSA 11:42 - Pre-Biopsy Blood and Urine Tests 13:29 - Equivocal MRI, Outside Imaging, and Community Practice 20:26 - Patient Factors and Practical Considerations 24:44 - Case: Elevated PSA and a Negative MRI 30:11 - Case: Biopsy Approach and Discordant Results 34:41 - Counseling on PSA Limitations and Overdiagnosis 37:05 - Biomarkers in Active Surveillance and Renaming Grade Group 1 40:56 - AI and the Future of Biomarkers 44:38 - Take-Home Points and Closing Remarks --- More about this episode The discussion covers equivocal MRI findings, patient counseling, and the practical impact of age, family history, and race when interpreting PSA levels. Through real cases, Dr. Lebastchi explains when he repeats a PSA, how he performs a templated transperineal biopsy, and why a negative MRI plus a negative biomarker can give him the confidence to forgo a biopsy. They also touch on active surveillance, the debate over renaming grade group 1 prostate cancer, and how AI may help future tests guide treatment intensity rather than just risk category. Dr. Lebastchi closes with the clinician’s obligation to know all available tests and use those that truly inform management. --- Resources Early Detection of Prostate Cancer: AUA/SUO Guideline (2023) https://www.auanet.org/guidelines-and-quality/guidelines/early-detection-of-prostate-cancer-guidelines Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study. Urol Oncol. 2022 https://pubmed.ncbi.nlm.nih.gov/35840465/ Using IsoPSA With Prostate Imaging Reporting and Data System Score May Help Refine Biopsy Decision Making in Patients With Elevated PSA. Urology. 2023 https://pubmed.ncbi.nlm.nih.gov/36965817/ Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. J Clin Oncol. 2022 https://pubmed.ncbi.nlm.nih.gov/35436144/ The influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer. J Natl Cancer Inst. 2023 https://pubmed.ncbi.nlm.nih.gov/37285311/ Dr. Amir Lebastchi, Keck Medicine of USC physician profile https://keckmedicine.org/provider/amir-h-lebastchi Dr. Ruchika Talwar, BackTable Urology contributor page https://www.backtable.com/shows/urology/contributors/dr-ruchika-talwar --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

    Not rated yet
  • Ep. 337 Advancements in Ureteroscopy for Stone Management with Dr. Karen Stern

    · 25 min

    How is suction technology changing what it means to be “stone-free” after ureteroscopy? On this episode of BackTable Urology, Dr. Ruchika Talwar welcomes Dr. Karen Stern, endourologist at Mayo Clinic Arizona, for a practical discussion of how ureteroscopy is evolving in the era of suction. They discuss how thin-slice CT has revealed just how much stone typically remains after surgery, why dusting versus fragmenting is now a patient-dependent choice, and what to consider when selecting between suction sheaths, aspiration scopes, and traditional access. --- Get the BackTable app https://www.backtable.com/app --- This podcast is supported by Dornier https://www.dornier.com/backtable (https://www.dornier.com/americas/products-item/hoover/) --- Timestamps 00:00 - Introduction 02:16 - Residual Stone and Defining Success 04:59 - Dusting, Fragmentation and Suction Devices 07:15 - Patient Selection, OR Setup and Laser Settings 11:39 - Evidence, Stone Clearance and Infection Risk 15:39 - Community Adoption and Technique Pearls 20:05 - Integrated Systems and Artificial Intelligence 22:29 - Take-Home Points and Closing Remarks --- More about this episode The doctors discuss patient selection, OR setup, stenting, and why stones over a centimeter benefit most from a suction approach. Dr. Stern shares her tips for suction device setup, irrigation and suction settings, and how even a short learning curve can make these techniques routine. They review infection risks, evidence on residual stone volume, pearls for community adoption, and look ahead to integrated laser-suction platforms and AI tools that may one day help define when a case is truly finished. Dr. Karen Stern closes with advice for urologists on the fence: every technology works, but the best choice is the one that fits your practice. --- Resources Are We Overreporting Post-Op Sepsis? The Difference Between Reported and Verified Rates of Post-Ureteroscopy Sepsis Using the Sepsis 3 Criteria at a Single Institution. J Endourol. 2026 https://doi.org/10.1177/08927790251394736 Flexible Ureteroscopy with a Flexible and Navigable Suction Ureteral Access Sheath Versus Mini-Percutaneous Nephrolithotomy for Treatment of 2-3 cm Renal Stones: An International, Multicenter, Randomized, Noninferiority Trial. Eur Urol. 2026 https://doi.org/10.1016/j.eururo.2025.06.001 Dr. Karen Stern, Mayo Clinic physician profile https://www.mayoclinic.org/biographies/stern-karen-l-m-d/bio-20464490 Dr. Ruchika Talwar, BackTable Urology contributor page https://www.backtable.com/shows/urology/contributors/dr-ruchika-talwar --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

    Not rated yet
  • Ep. 336 Biomarkers in Treatment Intensification for Prostate Cancer with Dr. Angela Jia

    · 47 min

    Same risk group, very different benefit. Can biomarkers help identify who needs treatment intensification in prostate cancer? On this episode of BackTable Urology, Dr. Ruchika Talwar and Dr. Angela Jia, a radiation oncologist at University Hospitals Cleveland Medical Center, break down the difference between prognostic and predictive biomarkers and how genomic testing is informing the way clinicians counsel patients. They review trial data suggesting that men with a low genomic score may gain little from adding hormone therapy, along with early prospective evidence that the luminal B subtype may help identify who benefits most from intensification. --- Get the BackTable app https://www.backtable.com/app --- This podcast is supported by Verasyte https://www.veracyte.com/ --- Timestamps 00:00 - Introduction 02:08 - Prognostic vs. Predictive Biomarkers 06:34 - The NRG/RTOG 0815 Biomarker Cohort 10:15 - Applying a Low Genomic Score in Clinic 15:16 - Genomic Classifiers After Prostatectomy 18:52 - RTOG 9601, SPPORT and the Salvage Evidence 24:39 - Stage Migration and the Case for an ARPI 28:13 - Ordering and Reading the Genomic Report 34:31 - Common Mistakes in Interpretation 37:31 - Where Genomics Could Go Next 41:03 - Reflex Testing, EMR Integration and AI 44:44 - Closing Remarks --- More about this episode The conversation covers practical application of test results, counseling with absolute risk numbers, and the pitfalls of stretching predictive claims beyond their evidence. Dr. Jia explains the limits of biopsy sampling, how stage migration with advanced imaging may shift baseline risk, and why a large portion of the genomic score remains unexplained by standard variables. The episode closes with a look at reflex testing, the potential role of AI, and the longer-term goal of giving patients clear, individualized benefit estimates for each treatment option. --- Resources NRG/RTOG 0815: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer (trial record) https://clinicaltrials.gov/study/NCT00936390 NRG-GU006 (BALANCE): A Phase II Randomized Trial of Salvage Radiotherapy With or Without Apalutamide in Recurrent Prostate Cancer (trial record) https://clinicaltrials.gov/study/NCT03371719 Feng FY, et al. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol. 2021 https://pubmed.ncbi.nlm.nih.gov/33570548/ Pollack A, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT). Lancet. 2022 https://pubmed.ncbi.nlm.nih.gov/35569466/ Zhao SG, et al. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 2017 https://pubmed.ncbi.nlm.nih.gov/28494073/ Patel KR, Nguyen PL, et al. Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413 and 9902 Phase 3 Trials. Eur Urol Oncol. 2026 https://pubmed.ncbi.nlm.nih.gov/39542826/ Grist E, et al. Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers (STAMPEDE). Cell. 2025 https://pubmed.ncbi.nlm.nih.gov/40865526/ Jia AY, et al. Cross-Comparison Individual Patient-Level Analysis of Three Gene Expression Signatures in Localized Prostate Cancer in Over 50,000 Men. JCO Precis Oncol. 2025 https://pubmed.ncbi.nlm.nih.gov/40479622/ Dr. Angela Jia, University Hospitals physician profile https://www.uhhospitals.org/doctors/Jia-Angela-1902338718 Dr. Ruchika Talwar, BackTable Urology contributor page https://www.backtable.com/shows/urology/contributors/dr-ruchika-talwar --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and…

    Not rated yet
  • Ep. 335 Diagnosis & Management of Neurogenic Bladder with Dr. Benjamin Brucker

    · 52 min

    How do you decide if a neurogenic bladder is a safety problem or a quality of life problem for each patient, and how do you move from guideline risk categories to a real surveillance plan? On this episode of BackTable Urology, Dr. Anjali Kapur interviews Dr. Benjamin Brucker, professor of urology and director of neuro-urology at NYU Langone Health, about navigating neurogenic lower urinary tract dysfunction. They start with the AUA and SUFU guideline framework, covering history, physical exam, mobility, cognition, voiding diaries, and risk stratification to sort patients into low, unknown, or high risk. Dr. Brucker outlines the findings that move a patient between categories and the workup needed, from renal ultrasound and urodynamics to identifying unsafe storage pressures and elevated post-void residual. --- Get the BackTable app https://www.backtable.com/app --- This podcast is supported by Medtronic --- Timestamps 00:00 - Introduction 03:20 - Initial Evaluation Under the AUA and SUFU Guidelines 05:39 - Risk Stratification and Surveillance 13:08 - Role of Fluoroscopy in Urodynamics 14:55 - Spinal Cord Injury and Detrusor Sphincter Dyssynergia 17:35 - Multiple Sclerosis, Parkinson Disease, and Stroke 23:13 - Cognitive and Functional Status in Therapy Selection 25:16 - Neuromodulation in the Neurogenic Population 29:07 - Catheter Management and Sphincterotomy 35:49 - Medical Therapy, Chemodenervation, and Surgical Escalation 42:50 - Asymptomatic Bacteriuria and Antibiotic Stewardship 46:04 - Gaps in Practice and Research on the Horizon 50:48 - Closing Remarks --- More about this episode The conversation dives into the nuances of managing neurogenic bladder by underlying disease, from detrusor sphincter dyssynergia after spinal cord injury to the variable patterns in multiple sclerosis, Parkinson disease, and stroke. Dr. Brucker explains the role of videourodynamics, the importance of matching therapy to cognition and mobility, and how to counsel patients on medical therapy, neuromodulation, catheterization, and surgery. They discuss antibiotic stewardship for asymptomatic bacteriuria, gaps between guidelines and real-world care, and what new devices and bladder transplant might mean for the future. The episode closes with a reminder that management is about treating the whole person, not just the diagnosis. --- Resources Neurogenic Lower Urinary Tract Dysfunction: AUA/SUFU Guideline https://www.auanet.org/guidelines-and-quality/guidelines/adult-neurogenic-lower-urinary-tract-dysfunction Ginsberg DA, Boone TB, Cameron AP, et al. The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Diagnosis and Evaluation. J Urol. 2021 https://doi.org/10.1097/JU.0000000000002235 Ginsberg DA, Boone TB, Cameron AP, et al. The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Treatment and Follow-up. J Urol. 2021 https://doi.org/10.1097/JU.0000000000002239 Vurture G, Peyronnet B, Palma JA, et al. Urodynamic Mechanisms Underlying Overactive Bladder Symptoms in Patients With Parkinson Disease. Int Neurourol J. 2019. https://doi.org/10.5213/inj.1938086.043 Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU). https://sufuorg.com/ American Urological Association (AUA) https://www.auanet.org/ First human bladder transplant, UCLA Health, 2025. https://www.uclahealth.org/news/release/first-human-bladder-transplant-performed-ucla Dr. Benjamin Brucker, NYU Langone Health physician profile https://nyulangone.org/doctors/1235295619/benjamin-m-brucker Dr. Benjamin Brucker, BackTable Urology contributor page https://www.backtable.com/shows/urology/contributors/dr-benjamin-brucker Dr. Anjali Kapur, BackTable Urology contributor page https://www.backtable.com/shows/urology/contributors/dr-anjali-kapur --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new…

    Not rated yet
  • Ep. 334 Optimizing Professional Growth with Career Coaching with Dr. Emilie Johnson and Dr. Angie Smith

    · 54 min

    What is the difference between mentorship, sponsorship, and coaching in a physician’s career, and how can coaching influence your professional development? On this episode of BackTable Urology, Dr. Helen Bernie interviews Dr. Emilie Johnson and Dr. Angie Smith about the transformative impact of career coaching for urologists. They break down how coaching differs from mentorship and sponsorship, who stands to benefit most, and the real value of having a conversation focused entirely on your goals and growth. --- Get the BackTable app https://www.backtable.com/app --- This podcast was developed in collaboration with Society of Women in Urology https://swiu.org/home.aspx --- Timestamps 00:00 - Introduction 03:21 - Mentorship, Sponsorship, and Coaching 06:23 - Paths Into Physician Coaching 11:39 - Who Should Seek a Coach 15:56 - What a Coach Does Differently 22:57 - Anatomy of a Coaching Session 28:21 - Coaching Frameworks and Tools 35:14 - Uncovering Unrecognized Goals 42:12 - Coaching Beyond the Workplace 47:16 - Advice for the Undecided Urologist 52:08 - Closing Remarks --- More about this episode The discussion explores what a coaching session looks like, from low-stakes one-offs to multi-month programs, and the frameworks and tools that stick, like strengths-based assessments, DiSC, and the career portfolio exercise. Dr. Smith shares insights from her credentialed coaching program, while Dr. Johnson explains how coaching changes everything from listening at home to decision-making in the OR. The episode closes with advice on finding the right coach, recognizing when you are ready, and why coaching is about unlocking what you already know. --- Resources Society of Women in Urology (SWIU) https://www.swiu.org/ Effect of a Professional Coaching Intervention on the Well-being and Distress of Physicians: A Pilot Randomized Clinical Trial (Dyrbye et al., JAMA Internal Medicine, 2019) https://doi.org/10.1001/jamainternmed.2019.2425 International Coaching Federation, credentialing and coach education requirements (ACC, PCC, MCC) https://coachingfederation.org/credentialing/prepare-for-icf-credential-application/education-training-requirements/ UNC School of Medicine coaching programs, Office of Faculty Affairs and Leadership Development https://www.med.unc.edu/facultyaffairs/coaching-culture/ VIA Character Strengths Survey, the free strengths assessment Dr. Smith recommends https://www.viacharacter.org/ CliftonStrengths (Gallup) https://www.gallup.com/cliftonstrengths/en/home.aspx --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

    Not rated yet
  • Ep. 333 Evaluating Adrenal Incidentalomas: A Urologist's Guide with Dr. Chris Anderson and Dr. Ben Ristau

    · 50 min

    Adrenal lesions now turn up on four to ten percent of cross-sectional scans, and every urologist needs a reliable way to sort out the harmless ones from the dangerous ones. On this episode of BackTable Urology, co-hosts Dr. Gina Badalato and Dr. Chris Anderson speak with Dr. Ben Ristau to share a practical, case-based framework for evaluating adrenal lesions. They walk through imaging criteria, the essential hormonal workup, size thresholds for surgery, the rare but crucial role of biopsy, and the operative planning that separates a smooth adrenalectomy from a crisis. --- Get the BackTable app https://www.backtable.com/app --- This podcast was developed in collaboration with Society of Academic Urologists https://sauweb.org/ --- Timestamps 00:00 - Introduction 03:42 - Imaging Criteria for Adrenal Adenoma 08:15 - Framework for Hormonal Workup 12:48 - Mild Autonomous Cortisol Secretion 16:20 - Adrenal Venous Sampling 21:12 - Genetic Syndromes and Pheochromocytoma 25:40 - Suspected Pheochromocytoma Case 31:19 - Alpha Blockade Before Surgery 35:36 - Intraoperative Hemodynamic Swings 40:50 - Adrenocortical Carcinoma Case 45:00 - Managing Adrenal Vein Avulsion 48:00 - Closing Remarks --- More about this episode The discussion opens with a 3.4 centimeter lipid-rich adenoma and the two questions that drive every evaluation, whether the lesion is malignant and whether it is functional. Dr. Ristau walks through the overnight 1 mg dexamethasone suppression test, the aldosterone to renin ratio, plasma free metanephrines and adrenal venous sampling, then explains why mild autonomous cortisol secretion is the most commonly missed diagnosis. Later cases cover preoperative alpha blockade for pheochromocytoma, the blood pressure swing that follows adrenal vein ligation, and open resection for suspected adrenocortical carcinoma. They close with pearls on surgical judgment, resident teaching, and the importance of systematic protocols in adrenal mass evaluation. --- Resources CUA guideline: Diagnosis, management, and follow-up of the incidentally discovered adrenal mass (endorsed by the AUA, Rowe et al., CUAJ 2023) https://cuaj.ca/index.php/journal/article/view/8248 European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, with ENSAT (Fassnacht et al., Eur J Endocrinol 2023) https://doi.org/10.1093/ejendo/lvad066 AACE / AAES Medical Guidelines for the Management of Adrenal Incidentalomas https://pro.aace.com/disease-state-resources/pituitary-and-neuroendocrine/clinical-practice-guidelines/american Discrepancies in the Recommended Management of Adrenal Incidentalomas by Various Guidelines (Journal of Urology) https://www.auajournals.org/doi/10.1097/JU.0000000000001342 Society of Academic Urologists https://sauweb.org/ --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

    Not rated yet
  • Ep. 332 The Basics of Advanced Prostate Cancer Management for Urologists with Dr. Kristen Scarpato and Dr. Jason Hafron

    · 48 min

    What does a urologist actually need to know to confidently manage advanced prostate cancer in the clinic? On this episode of BackTable Urology, host Dr. Ruchika Talwar interviews Dr. Kristen Scarpato, director of the advanced prostate cancer clinic at Vanderbilt University Medical Center, and Dr. Jason Hafron, chief medical officer of the Michigan Institute of Urology. They break down how the landscape has shifted, why more patients stay in urology for treatment, and how to select and monitor therapy based on disease state, comorbidities, and patient goals. --- Get the BackTable app https://www.backtable.com/app --- This podcast is supported by Bayer https://www.bayer.com --- Timestamps 00:00 - Introduction 02:41 - Shift to Urology-Led Advanced Prostate Management 07:07 - Sorting Therapies by Disease State 10:33 - Treatment Intensification and Doublet Therapy 17:54 - ARPI Selection and the Four Ps Framework 25:46 - Managing Financial Toxicity 29:30 - Monitoring, Labs, and Imaging 34:11 - Red Flags and Comanagement 36:49 - When to Refer to Medical Oncology 41:11 - Future Directions and Practice Economics 46:33 - Closing Remarks --- More about this episode The discussion covers sorting therapies by disease state rather than drug class, doublet and triplet intensification, the nuances of choosing between abiraterone, enzalutamide, apalutamide, and darolutamide, and Dr. Hafron’s “four Ps” framework for drug selection. Dr. Scarpato addresses financial toxicity, surveillance protocols, and red flag symptoms. Both guests share their referral triggers for medical oncology, approaches for oligometastatic disease and metastasis-directed therapy, and practical tips for running an advanced prostate cancer clinic. --- Resources Advanced Prostate Cancer: AUA/SUO Guideline https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4 (JCO) https://ascopubs.org/doi/10.1200/JCO-25-02834 ARACOG (AFT-47): Darolutamide vs Enzalutamide and Cognitive Function, ClinicalTrials.gov NCT04335682 https://clinicaltrials.gov/study/NCT04335682 ARASENS: Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer (NEJM) https://www.nejm.org/doi/full/10.1056/NEJMoa2119115 PSMAddition: 177Lu-PSMA-617 Plus Standard of Care in mHSPC, ClinicalTrials.gov NCT04720157 https://clinicaltrials.gov/study/NCT04720157 Medicare Plan Finder, referenced on air for comparing Part D out-of-pocket drug costs https://www.medicare.gov/plan-compare/ --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

    Not rated yet
  • Ep. 331 Transitioning an Independent Practice to an Academic Urology Program with Dr. Javier Castillo

    · 1 hr 5 min

    How can private practice and academic residency programs work together to shape the next generation of urologists? On this episode of BackTable Urology, Dr. Jose Silva interviews Dr. Javier Castillo about launching an academic residency within a busy private urology group in Puerto Rico. They highlight the business, training, and research challenges involved, as well as the innovations that make real collaboration possible. Dr. Castillo also reflects on why building character in trainees is just as important as teaching surgical skill. --- Get the BackTable app https://www.backtable.com/app --- Timestamps 00:00 - Introduction 04:04 - Launching a Residency and Building the Practice 08:13 - Teaching in the OR and Progressive Responsibility 13:58 - Clinic, Administration, and Resident Training 16:38 - Expanding BPH Treatment Options 25:21 - Creating a Research Culture and AI Projects 32:42 - AI Uroflow Project and Follow Up 40:21 - BPH Case Workup and Shared Decision-Making 47:11 - Patient Goals and Procedure Selection 55:43 - Sacral Neuromodulation and New Technologies 01:00:19 - Teaching Character and Mentorship 01:03:07 - Closing Remarks --- More about this episode The conversation explores how to teach residents in the OR while maintaining efficiency, build a research culture, and leverage advanced technologies like AI-driven home uroflowmetry. Dr. Castillo and Dr. Silva discuss individualized BPH treatment, expanding procedural options, and aligning care with patient goals. The episode closes with practical lessons on mentorship, character, and the strategies that make a residency program thrive for both trainees and patients. --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

    Not rated yet
  • Ep. 330 Establishing a Comprehensive Cancer Survivorship Practice with Dr. Hiren Patel

    · 1 hr 4 min

    How can reconstructive urologists improve quality of life for cancer survivors beyond the initial cure? On this episode of BackTable Urology, Dr. George Koch interviews Dr. Hiren Patel about building a comprehensive survivorship practice that addresses the long-term needs of patients following genitourinary cancer treatment. They discuss moving beyond post-prostatectomy ED and incontinence to include management of radiation sequelae, immunotherapy effects, and urethral strictures, as well as the role of patient-centered communication, care coordination, and technology. --- Get the BackTable app https://www.backtable.com/app --- Timestamps 00:00 - Introduction 04:26 - Redefining Survivorship 11:29 - Why Survivorship Practices Matter 17:53 - Workup and Aligning Care 21:05 - Managing Active Cancer Scenarios 27:20 - Building a Survivorship Program 30:12 - Growing Referrals and Optimizing Workflow 39:24 - System Support and Research Gaps 44:04 - Tech Advances in Reconstruction 48:50 - Single-Port Retroperitoneal Case 59:55 - Tips, Tricks, and Wrap-Up --- More about this episode The conversation covers patient expectation setting, logistics of establishing a survivorship clinic, aligning care with patient goals, and multidisciplinary collaboration with oncology and primary care. Dr. Patel highlights strategies to reduce ER visits and system burden, the importance of continuity, and advances such as single-port robotic retroperitoneal ureteral reconstruction. The episode concludes with practical tips on trust-building, workflow optimization, and advocating for survivorship programs within larger health systems. --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

    Not rated yet
  • Ep. 329 Surgical Approaches to Bladder Outlet Obstruction with Dr. John DiBianco

    · 1 hr 0 min

    With so many treatment options for bladder outlet obstruction, how do you select the best approach for each patient? On this episode of BackTable Urology, host Dr. Jose Silva is joined by Dr. John DiBianco for a practical discussion on evaluating lower urinary tract symptoms and matching patients with the right intervention. They emphasize confirming that symptoms are truly due to benign prostatic hyperplasia (BPH) before proceeding, and walk through triggers for intervention, including quality-of-life impact, UTIs, renal impairment, high post-void residual, bladder stones, and retention. --- Get the BackTable app https://www.backtable.com/app --- Timestamps 00:00 - Introduction 03:24 - Complex BPH Referrals and Symptom Assessment 06:07 - Deciding When to Operate 11:12 - Imaging and Prostate Sizing 14:27 - When to Use Cystoscopy and Urodynamics 16:43 - Incorporating Patient Preferences 21:53 - Medical Therapy and Pills 23:45 - Decision Aids and Personal Experience 27:13 - Managing HoLEP Complications and Leakage 32:57 - Advances in HoLEP Technique 36:07 - TURP Indications and Outcomes 38:36 - Special Considerations: Radiation and UroLift 39:58 - ThULEP vs. HoLEP 41:17 - Redo Surgery Strategies 43:52 - Counseling Through Case Scenarios 56:16 - Future Directions in BPH Treatment 59:05 - Wrap Up and Credits --- More about this episode The conversation covers everything from surveillance and imaging-based prostate sizing to when to use cystoscopy and urodynamics for complex or high-risk patients. Drs. Silva and DiBianco compare procedure options like HoLEP, TURP, GreenLight, UroLift, PAE, iTind, and aquablation, highlighting how factors like prostate size, morphology, history, and patient goals drive decision-making. They discuss durability, redo surgery issues, management of radiation patients, and postoperative care including leakage management and pelvic floor therapy. The episode wraps up with future directions in BPH procedures and practical counseling tips for patient satisfaction. --- Resources Love this episode? Check out BackTable.com and search “BPH” to get more information on a variety of the surgical options discussed in this episode, including HoLEP, Aquablation, PAE, and more! Further resources include the BackTable App, which has a course on treating Benign Prostatic Hyperplasia. --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

    Not rated yet
  • Ep. 328 Shared Decision-Making in Overactive Bladder Care with Dr. Jannah Thompson

    · 56 min

    Can shared decision-making and patient support change the treatment journey for overactive bladder? On this episode of BackTable Urology, host Dr. Suzette Sutherland and OAB expert Dr. Jannah Thompson discuss how patient education, clear counseling, and ongoing follow-up improve care for patients with overactive bladder and urge incontinence. They cover practical strategies for building an effective OAB care pathway, staff training for better patient navigation, and proactive approaches that increase adherence and access to advanced therapies. --- Get the BackTable app https://www.backtable.com/app --- This podcast is supported by Medtronic Pelvic Health https://urgencyisreal.com/ --- Timestamps 00:00 - Introduction 04:00 - Shared Decision-Making 06:51 - Clinic Efficiency 10:38 - Expanding OAB Therapy Options 12:27 - Long-Term OAB Care 17:41 - Building an OAB Program 18:18 - Staff Training and Follow-Up 25:32 - OAB Navigator Implementation 27:14 - Navigation Outcomes 28:39 - Scaling with Staff and Epic 30:35 - Algorithm Resources 34:08 - Neuromodulation Advances 38:37 - New Tibial and Battery-Free Devices 40:56 - Quality of Life in OAB Care 46:11 - Access and Adoption 51:22 - Streamlining Therapy Discussions 52:47 - Closing Remarks --- More about this episode The conversation explores the diverse landscape of OAB treatment options, the evolving role of neuromodulation, and how new technologies are enabling more personalized care. Dr. Thompson shares insights on empowering staff as part of the clinical team, leveraging patient navigators to boost follow-up and advanced therapy uptake, and the importance of integrating patient preferences and lifestyle factors into every decision. They emphasize that quality of life, not just symptom control, should be central to OAB management, and discuss how to engage patients as partners throughout their treatment journey. --- Resources Patient navigation for overactive bladder improves access to care https://link.springer.com/article/10.1007/s00192-019-04085-7 --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

    Not rated yet
  • Ep. 327 Clinical Approaches to Testicular Cancer Management with Dr. Sean Kern and Dr. Sam Funt

    · 48 min

    What are the key considerations for choosing between surveillance, surgery, and chemotherapy in testicular cancer? On this episode of BackTable Urology, host Dr. Rich Matulewicz is joined by Dr. Sean Kern and Dr. Sam Funt for an in-depth discussion on clinical approaches to testicular cancer. They start with a real-world case, reviewing initial evaluation, imaging, tumor markers, and counseling on fertility, body image, and hypogonadism. The conversation highlights how nuanced patient selection influences decisions between surveillance, surgical intervention, and adjuvant chemotherapy. --- Get the BackTable app https://www.backtable.com/app --- Timestamps 00:00 - Introduction 01:40 - Initial Case Workup and Counseling 06:28 - Why Testicular Cancer Happens 09:17 - Management Considerations with Post-Orchiectomy Pathology 19:21 - RPLND Benefits and Drawbacks 23:39 - Surveillance Schedule and Long Term Follow Up 28:17 - Second Tumor Risk 30:36 - Evolving Seminoma Treatment 37:57 - RPLND Selection Factors 40:10 - Adjuvant Chemo Debate and Pathology 46:06 - Closing Takeaways --- More about this episode The episode explores postoperative management, including long-term surveillance, risk of a second tumor, and strategies for lifelong follow-up. The doctors discuss evolving practice in the management of low-volume stage II seminoma, the increasing use of RPLND to reduce chemo and radiation exposure, and the importance of extended patient counseling over multiple visits. The discussion emphasizes individualized care, the role of new diagnostics, and the need for reassurance and support throughout the treatment journey. --- Resources Society of Urologic Oncology https://suonet.org/home.aspx --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

    Not rated yet
  • Ep. 326 Strategies for Surgical Training During High-Stakes Operations with Dr. Kelvin Moses

    · 50 min

    How can high-stakes surgical cases be optimized for teaching while ensuring patient safety and trainee growth? On this episode of BackTable Urology, Dr. Ruchika Talwar interviews Dr. Kelvin Moses about intentional strategies for surgical education, especially during complex urologic oncology operations. They discuss workflows that prioritize preoperative planning, structured debriefs, and progressive autonomy for trainees, as well as the importance of psychological safety and open communication with patients and families. --- Get the BackTable app https://www.backtable.com/app --- Timestamps 00:00 - Introduction 02:19 - Teaching In High Stakes Cases 07:57 - Rethinking See One, Do One, Teach One 10:24 - Assessing Trainee Readiness 14:29 - Preop Preparation 16:06 - Teaching Cues in the OR 17:42 - Tips for Trainees 21:40 - Intentional Teaching 24:02 - Teaching Rare and Complex Cases 26:40 - Anticipating Complications and Debrief After Disaster 33:09 - Psychological Safety In the OR 37:41 - Reflections on Past, Current, and Future Training Models 43:56 - Patients And Trainees 46:51 - Takeways --- More about this episode The conversation explores practical intraoperative teaching cues, tips for trainees such as visualization, recording cases, and repetition, and methods for relating rare cases to more common procedures. Dr. Moses reflects on the strengths and challenges of past, present, and future training models, including the debate over whether surgical education has gone “too soft.” The episode emphasizes the value of mentorship, transparency with patients, and the need to continually adapt surgical training for the next generation. --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

    Not rated yet
  • Ep. 325 Navigating the PSA Maze in Urology with Dr. Tarik Benidir

    · 45 min

    Is an elevated prostate-specific antigen (PSA) the beginning or the end of the prostate cancer workup? On this episode of BackTable Urology, Dr. Ruchika Talwar interviews Dr. Tarik Benidir to explore the “PSA problem,” explaining why PSA is biologically useful but clinically imprecise, often leading to false positives, unnecessary biopsies, and detection of indolent disease. They discuss a rational, patient-centered approach to elevated PSA, including when to repeat the test, how to interpret results in the context of age, race, family history, and prostate size, and the use of PSA density and age-adjusted norms instead of rigid cutoffs. --- Get the BackTable app https://www.backtable.com/app --- This podcast is supported by Cleveland Diagnostics https://www.isopsa.com/ --- Timestamps 00:00 - Introduction 04:03 - Why PSA Can Be Misleading 06:43 - Approach to Elevated PSA and Initial Workup 09:51 - MRI, PSA Density, and Biomarker Testing 14:31 - Guidelines, Diagnostics, and When to Biopsy 20:16 - Comparing 4K, IsoPSA, and Other Biomarkers 25:23 - Choosing Between Transperineal and Transrectal Biopsy 28:42 - Management Considerations for Elderly and Comorbid Patients 33:09 - Active Surveillance, Recurrence, and Long-Term Monitoring 40:47 - Key Takeaways and Closing Remarks --- More about this episode The conversation highlights the role of reflex biomarkers, MRI scans, and selective biopsy strategies to reduce unnecessary procedures and focus on identifying clinically significant cancers. Dr. Benidir explains how to weigh MRI results, when to use biomarkers, and how to approach decisions in elderly or comorbid patients. They also discuss new biopsy modalities, active surveillance, and future directions for optimizing PSA-based screening and management. --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

    Not rated yet